Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
CERVICAL: METASTATIC: FIRST LINE: IMMUNOTX: KEYNOTE 826

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Title
Merck Sharp & Dohme Corp MK-3475-826 (CERVICAL KEYNOTE-826)
Study Title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Site Link
Malignancy
Cervical, cervix cancer
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
First line
Investigational Agent
Pembrolizumab
Drug Class
PD-1 antibody
PI
Adam ElNaggar, MD
Sponsor
Merck Sharp and Dohme Corp.
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Persistent, recurrent, or metastatic cervical cancer (squamous cell, adenosquamous, or adenocarcinoma) not amenable to curative treatment
  • No prior treatment with systemic chemotherapy
  • Measurable disease
  • ECOG PS 0-1
  • No known CNS metastases
  • No other malignancy within 3 years (other than NMSC, in situ cancers)
  • No chronic steroid therapy
  • No autoimmune disease
  • No known HBV, HCV, HIV
Objective

Primary- PFS, OS

Secondary- ORR, DOR, 12mo PFS, Safety, QOL

Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
squamous cell, adenosquamous, or adenocarcinoma of cervix
Dosing Frequency
Control Agents
Chemo alone
Study Protocol
Randomized
Yes
X